ATARA BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $100.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-28.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2024-03-28
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-12-31 was $400.00K, a 92.45% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-09-30 was $100.00K, a 96.15% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-06-30 was $200.00K, a 96.88% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-03-31 was $3.10M, a 36.73% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $100.00K, a 87.50% decline from fiscal 2021.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $800.00K, a 20.00% decline from fiscal 2020.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $1.00M, a 73.68% decline from fiscal 2019.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $3.80M, a 80.21% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|---|
| 2022-12-31 | $100.00K 10-K · filed 2024-03-28 | ||||
| 2021-12-31 | $800.00K 10-K · filed 2023-02-08 | ||||
| 2020-12-31 | $1.00M 10-K · filed 2023-02-08 | ||||
| 2019-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $500.00K derived: sum of 2 quarters · filed 2022-02-28 | $700.00K derived: sum of 3 quarters · filed 2022-02-28 | $3.80M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $300.00K derived: sum of 2 quarters · filed 2019-11-07 | $3.40M 10-Q · filed 2019-11-07 | $8.70M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $3.30M 10-Q · filed 2019-08-08 | $8.60M derived: sum of 3 quarters · filed 2021-03-01 | $11.20M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-03-31 | $3.10M 10-Q · filed 2019-05-09 | $8.40M derived: sum of 2 quarters · filed 2021-03-01 | $11.00M derived: sum of 3 quarters · filed 2021-03-01 | $17.40M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2018-12-31 | $5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $7.90M derived: sum of 2 quarters · filed 2021-03-01 | $14.30M derived: sum of 3 quarters · filed 2021-03-01 | $19.20M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $2.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $9.00M derived: sum of 2 quarters · filed 2019-11-07 | $13.90M 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $6.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $11.30M 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | $4.90M 10-Q · filed 2019-05-09 | ||||
| 2017-12-31 | $200.00K 10-K · filed 2020-02-27 | ||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $183.00K derived: sum of 2 quarters · filed 2019-02-26 | $190.00K derived: sum of 3 quarters · filed 2019-02-26 | $200.00K 10-K · filed 2019-02-26 | |
| 2016-09-30 | $183.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $190.00K derived: sum of 2 quarters · filed 2017-11-09 | $200.00K 10-Q · filed 2017-11-09 | $400.00K derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $17.00K 10-Q · filed 2017-08-07 | $26.00K 10-Q · filed 2016-08-08 | $217.00K derived: sum of 3 quarters · filed 2018-02-27 | $591.00K derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $10.00K 10-Q · filed 2017-05-04 | $210.00K derived: sum of 2 quarters · filed 2018-02-27 | $584.00K derived: sum of 3 quarters · filed 2018-02-27 | ||
| 2015-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $574.00K derived: sum of 2 quarters · filed 2018-02-27 | $600.00K 10-K · filed 2018-02-27 | ||
| 2015-09-30 | $374.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $400.00K 10-Q · filed 2016-11-04 | |||
| 2015-06-30 | $26.00K 10-Q · filed 2016-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |